Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Carcinoma » Carcinoma, Squamous Cell
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Squamous Cell » Carcinoma, Squamous Cell
Description
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) MeSH
Hierarchy View
Subtype Terms (3)
Bowen's Disease
8 drugs (6 approved, 2 experimental)
Esophageal Squamous Cell Carcinoma
99 drugs (36 approved, 63 experimental)
Squamous Cell Carcinoma of Head and Neck
653 drugs (189 approved, 464 experimental)
Approved Indicated Drugs (6)
Phase 3 Indicated Drugs (30)
Phase 1 Indicated Drugs (73)
Other Experimental Indicated Drugs (22)
Organization Involved with Phase 4 Indications (17)
Organization Involved with Phase 3 Indications (143)
Arbeitsgemeinschaft medikamentoese Tumortherapie
Associazione Volontari Pazienti Oncologici
Biotech Pharmaceutical Co., Ltd.
Blokhin's Russian Cancer Research Center
Clinica Universidad de Navarra
DAHANCA Danish Head and Neck Group
Danish Center for Interventional Research in Radiation Oncology
Danish Head and Neck Cancer Group
ECOG-ACRIN Cancer Research Group
GORTEC (Head and Neck Oncology and Radiotherapy Group)
Groupe Oncologie Radiotherapie Tete et Cou
Grupo de Investigación Clínica en Oncología Radioterapia
Guangzhou Double Bioproducts Co., Ltd
Hospital Regional Universitario Carlos Haya
Huai'an First People's Hospital
Huai'an Second People's Hospital
Huazhong University of Science and Technology
Innovent Biologics (Suzhou) Co. Ltd.
International Atomic Energy Agency
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Jiangxi Provincial Cancer Hospital
National Cancer Institute (NCI)
National Cheng Kung University
People's Liberation Army of China
Radiation Therapy Oncology Group
Radiotherapeutisch Instituut Friesland
Royal Marsden Hospital NHS Trust
Organization Involved with Phase 2 Indications (324)
All India Institute of Medical Sciences
Anhui College of Traditional Chinese Medicine
Australasian Gastro-Intestinal Trials Group
Badalona Hospital Germans Trias i Pujol
Beijing Konruns Pharmaceutical Co., Ltd.
Bhagwan Mahaveer Jain Hospital
Canadian Institutes of Health Research (CIHR)
Case Western Reserve University
Center for Clinical and Cosmetic Research
Central India Cancer Research Institute, Nagpur
Centre Hospitalier of Chartres
China Three Gorges University, Yichang, China
Chinese Society of Lung Cancer
Christian Medical College, Vellore, India
City of Hope National Medical Center
Clinuvel Pharmaceuticals Limited
CSM Medical University, Lucknow
Curie Manavata Cancer Center, Nashik, India
Deenanath Mangeshkar Hospital & Research Centre
Department of Radiation Oncology
Dynavax Technologies Corporation
Eastern Cooperative Oncology Group
Elisabeth-TweeSteden Ziekenhuis
Federation Francophone de Cancerologie Digestive
Fundação de Amparo à Pesquisa do Estado de São Paulo
GKNM Hospital, Coimbatore, India
Government Medical College, Aurangabad, India
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
GROUPE ONCOLOGIE RADIOTHERAPIE TETE ET COU
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Grupo Espanol Multidisciplinario del Cancer Digestivo
Gruppo Oncologico del Nord-Ovest
Gynecologic Oncology of Indiana
HealthCare Global Enterprise Ltd.
Hellenic Cooperative Oncology Group
Hoosier Cancer Research Network
Icahn School of Medicine at Mount Sinai
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Instituto do Cancer do Estado de São Paulo
International Rare Cancers Initiative (IRCI ) This study is indorsed by IRCI
Istituto Oncologico Veneto IRCCS
James and Esther King Biomedical Research Program
Jaslok Hospital and Research Centre, Mumbai, India
Katholieke Universiteit Leuven
Korean South West Oncology Group
Laboratorio Elea S.A.C.I.F. y A.
Lithuanian University of Health Sciences
Meenakshi Ammal Dental College and Hospital
Memorial Hermann Health System
Memorial Sloan-Kettering Cancer Center
National Cancer Institute, France
National Comprehensive Cancer Network
National Institute of Dental and Craniofacial Research (NIDCR)
National Institutes of Health (NIH)
National University of Singapore
New Mexico Cancer Care Alliance
Oregon Health and Science University
Pharmaceutical Research Associates, Inc. (PRA)
Regional Cancer Centre, Trivandram
Russian Academy of Medical Sciences
Samyang Biopharmaceuticals Corporation
SignalRX Pharmaceuticals, Inc.
Spanish Oncology Genito-Urinary Group
State University of New York, Buffalo
State University of New York, Syracuse
Sunshine Lake Pharma Co., Ltd.
The First People's Hospital of Hangzhou
The Jewish General Hospital, Montreal QC, Canada
The Kidney Foundation of Canada
The University of Texas, Dallas
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
University of California, Los Angeles
University of California, San Diego
University of California, San Francisco
University of Erlangen-Nuremberg
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern California
University of Texas at Houston
University of Texas, San Antonio
Vlaams Instituut voor Biotechnologie (VIB)
Organization Involved with Phase 1 Indications (76)
American Society of Clinical Oncology
Baromedical Research Foundation
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Cooperative Research Centre for Biomedical Imaging Development
Eastern Virginia Medical School
Infinity Pharmaceuticals, Inc.
Medical University of South Carolina
Methodist Cancer Center, Houston, Texas
National Institute on Deafness and Other Communication Disorders (NIDCD)
Organization Involved with Other Experimental Indications (25)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
